[Diagnosis and therapy of Gaucher disease. Current recommendations of German therapy centers in the year 2000].
BACKGROUND
Gaucher's disease is the autosomally recessively inherited deficiency of the lysosomal enzyme glucocerebrosidase. Increasing storage of glucocerebrosides leads to a multisystem disease, the prevalence of which is about 1:40,000 in central Europe and up to 1:2,000 in some other countries (e.g. Israel). The acute and chronic neuronopathic forms of the disease (formerly defined as Gaucher types 2 and 3) account for only 5 to 10% of all Gaucher patients in Central Europe and Germany and are thus less frequent than the non-neuronopathic disease (formerly defined as Gaucher type 1). Gaucher's disease is usually associated with spleno- and hepatomegaly, fatigue, skeletal complications, and several corresponding hematological and laboratory abnormalities. In 5 to 10% of the patients there are also central nervous symptoms such as myoclonic seizures, oculomotoric apraxia and a slight mental retardation.


METHODS
Four specialized centers care for more than 2/3 of all German Gaucher patients today. These centers present their consensus recommendations for state-of-the-art diagnosis and treatment of Gaucher's disease.


RESULTS
Recent epidemiological data indicate that only 10 to 20% of all Gaucher patients are correctly diagnosed (and treated) in Germany. The diagnosis today can be done in all patients by noninvasive methods, i.e. determination of the glucocerebrosidase activity in peripheral leukocytes and of the genetic defect. The current enzyme replacement therapy with glucocerebrosidase has proven effective to improve and often normalize hematological abnormalities, hepatosplenomegaly, skeletal complications and quality of life, provided that the therapy is started early and is given at adequate dosages.


CONCLUSIONS
In view of the availability of an effective therapy, efforts should be made to increase the awareness of Gaucher's disease in differential diagnosis, to help to diagnose the disease with noninvasive techniques at early stages, and to provide practical guidelines for adequate treatment.
Niederau
C
C
Klinik für Innere Medizin, St.-Josef-Hospital Oberhausen, Akademisches Lehrkrankenhaus, Universität Essen. claus.niederau@uni-duesseldorf.de
Rolfs
A
A
vom Dahl
S
S
Häussinger
D
D
Poll
L W
LW
Mengel
E
E
Beck
M
M
D002869:Chromosome Aberrations / Q000235:genetics; D025063:Chromosome Disorders; D004305:Dose-Response Relationship, Drug; D005776:Gaucher Disease / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy; D005808:Genes, Recessive; D005858:Germany; D005962:Glucosylceramidase / Q000008:administration & dosage; D006801:Humans; D009460:Neurologic Examination; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
D005962:Glucosylceramidase
Diagnose und Therapie des Morbus Gaucher. Aktuelle Empfehlungen der deutschen Therapiezentren im Jahr 2000.